Immunotherapeutic agents
US6180644A · kind A · utility
13Cited by
3References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 1999 |
| Grant date | Jan 30, 2001 |
| Priority date | — |
| Expiry date | Jun 11, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D209/46
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel amides and imides are inhibitors of tumor necrosis factor.alpha. and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. Typical embodiments include 3-(1,3-dioxobenzo[f]isoindol-2-yl)-3-(3-cyclopentyloxy-4-methoxyphenyl)pro pionamide and 3-(1,3-dioxo-4-azaisoindol-2-yl)-3-(3,4-dimethoxyphenyl)propionamide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.